Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

about

Experience of the use of velaxin (venlafaxine) in anxious depression.The relationship between physical functional limitations, and psychological distress: Considering a possible mediating role of pain, social support and sense of mastery.

P2860

Q46113546-675CB88B-AD21-4DEB-A39E-86981F21CAD1 Q47554234-12D75B6B-88F0-4688-AB35-117BF6F68EE5

P2860

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

Item

http://www.wikidata.org/entity/Q51902879

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@en

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@nl

type

Item

label

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@en

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@nl

prefLabel

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@en

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@nl

P1476

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

@en

P2093

Marzol PC

http://www.w3.org/2001/XMLSchema#string

Pollack MH

http://www.w3.org/2001/XMLSchema#string

P2860

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

Emergence of depressive symptoms in patients receiving alprazolam for panic disorder.

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Clinical pharmacokinetics of nefazodone.

Problems with the differentiation of anxiety and depression.

Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research.

Venlafaxine: a structurally unique and novel antidepressant.

Progress in psychiatry (2).

Use of benzodiazepines in anxiety disorders.

Drug-drug interactions involving antidepressants: focus on venlafaxine.

P304

23-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1092852900007781

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2000-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17545962

http://www.w3.org/2001/XMLSchema#string

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

about

P2860

P2860

Pharmacotherapeutic options in the treatment of comorbid depression and anxiety.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698